Jessica J. Kandel to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications Jessica J. Kandel has written about Vascular Endothelial Growth Factor A.
Connection Strength
1.235
-
Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol. 2009 Jan; 34(1):79-87.
Score: 0.278
-
Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep. 2003 Sep-Oct; 10(5):1271-4.
Score: 0.192
-
Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol. 2009 Feb; 34(2):401-7.
Score: 0.070
-
Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res. 2008 Jan; 6(1):1-9.
Score: 0.065
-
Antiangiogenic therapy for the treatment of pediatric solid malignancies. Semin Pediatr Surg. 2004 Feb; 13(1):53-60.
Score: 0.049
-
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res. 2004 Jan; 2(1):36-42.
Score: 0.049
-
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003 Jun 24; 100(13):7785-90.
Score: 0.047
-
VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 2003 Apr; 3(2):263-76.
Score: 0.047
-
Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.
Score: 0.046
-
p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg. 2002 Mar; 37(3):523-7.
Score: 0.043
-
Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg. 2002 Mar; 37(3):528-32.
Score: 0.043
-
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001 Aug; 36(8):1177-81.
Score: 0.042
-
Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg. 2000 Jun; 35(6):977-81.
Score: 0.038
-
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000 Jan; 35(1):30-2; discussion 32-3.
Score: 0.037
-
Pathological angiogenesis in a murine model of human Wilms' tumor. J Pediatr Surg. 1999 May; 34(5):676-9.
Score: 0.036
-
Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor. J Pediatr Surg. 1999 May; 34(5):743-7; discussion 747-8.
Score: 0.036
-
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol. 2012 Jun; 38(6):1019-29.
Score: 0.022
-
A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008 Jun 15; 68(12):4727-35.
Score: 0.017
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
Score: 0.016
-
Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res. 2006 Apr 15; 66(8):4378-84.
Score: 0.014
-
TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther. 2004 Mar; 3(3):335-43.
Score: 0.012
-
Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003 Mar; 38(3):308-14; discussion 308-14.
Score: 0.012
-
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11399-404.
Score: 0.011
-
Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg. 2002 Mar; 37(3):518-22.
Score: 0.011